United States - Pagina 5 di 6 - Fideres

Pay-to-Delay: Biosimilars and the Cost of Competition

Key Points Biosimilar drugs are non-generic alternatives to traditional biologic medicines, that sell at a fraction of the price. Scrutiny

Gennaio 29, 2019

The Hidden Cost of No-Poach Agreements

Key Points Fideres’s investigation found preliminary economic evidence to suggest widespread wage suppression in occupations within the healthcare and fast-food

Settembre 3, 2018

Dream Sold, Reality Bit: The Mis-Selling of Financial Hedging Products

Key Points Fideres shows that commercial borrowers may have significantly overpaid on interest payments as a result of banks selling

Maggio 16, 2018

Municipal Bonds: Low Yields, High Questions

Key Points Fideres finds that underwriters systematically misprice US municipal bonds (“Muni Bonds”). We estimate that, between 2006 and 2015,

Structured Ratings: Credit Agencies Revisited

Key Points It is generally accepted that rating agencies did a poor job rating structured credit products in the years

Gennaio 16, 2018

CDOR Under Pressure: Canada’s Rate Benchmark in Trouble

Key Points Between September 2007 and September 2009, the Canadian Dollar Offered Rate (CDOR) was potentially suppressed by 30 –

Ottobre 9, 2017

Generic Drug Prices: Why U.S. Costs Keep Rising

Key Points Generic drug price increases may be more widespread than the scope of any current lawsuit. Fideres has identified

Gennaio 13, 2017

Fideres Partners Supports Filing Of Econazole Price Fixing Class Action Against Major Generic Drug Manufacturers

Fideres Partners LLP, a leading independent economic consulting firm specializing in expert economic analysis for complex litigation, today announced its

Dicembre 30, 2016

Fideres Advises In Generic Drug Pricing Clobetasol Propionate Case

Fideres provided comprehensive consulting expert analysis in NECA IBEW Welfare Trust Fund v. Akorn Inc. (Case No. 1:16-cv-08109), part of

Ottobre 20, 2016

Twombly Or Not Twombly?

Key Points We assess the impact of the Twombly decision on US antitrust class actions. The number of filings has

Ottobre 7, 2016